VF (4771) reported revenue of NT$334.7 million for Oct 2026, -5.8% year on year and -15.2% from the previous month. Revenue for Jan–Oct 2026 was NT$3.71 billion (+28.2% year on year).
In Oct 2026, it ranked No. 29 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$334.7 million | -5.8% | -15.2% |
| Sep 2026 | NT$394.5 million | +24.9% | -9.7% |
| Aug 2026 | NT$436.9 million | +70.6% | +38.9% |
| Jul 2026 | NT$314.6 million | +11.7% | -20.3% |
| Jun 2026 | NT$394.9 million | +31.3% | +3.6% |
| May 2026 | NT$381 million | +33.1% | -9.3% |
| Apr 2026 | NT$420.2 million | +47.3% | +20.7% |
| Mar 2026 | NT$348.1 million | +18.2% | +10.6% |
| Feb 2026 | NT$314.7 million | +21.3% | -14.5% |
| Jan 2026 | NT$368 million | +43.4% | +27.9% |
| Dec 2025 | NT$287.6 million | +29.2% | -6.6% |
| Nov 2025 | NT$308 million | +35.0% | -13.3% |
| Oct 2025 | NT$355.3 million | +14.3% | +12.5% |
| Sep 2025 | NT$315.9 million | +22.0% | +23.4% |
| Aug 2025 | NT$256 million | +2.3% | -9.1% |
| Jul 2025 | NT$281.7 million | +20.8% | -6.4% |
| Jun 2025 | NT$300.9 million | +37.8% | +5.1% |
| May 2025 | NT$286.2 million | +10.0% | +0.3% |
| Apr 2025 | NT$285.3 million | +13.6% | -3.1% |
| Mar 2025 | NT$294.6 million | +29.7% | +13.6% |
| Feb 2025 | NT$259.4 million | +18.3% | +1.1% |
| Jan 2025 | NT$256.6 million | -20.3% | +15.2% |
| Dec 2024 | NT$222.7 million | -9.4% | -2.4% |
| Nov 2024 | NT$228.1 million | -14.4% | -26.7% |
| Oct 2024 | NT$311 million | +5.6% | +20.1% |
Jan–Oct 2026 cumulative: NT$3.71 billion (+28.2% YoY)
Other Biotech & Medical companies
Compare with peers: VF vs PEC / VF vs Lotus Pharm / VF vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16